Josh Riggs - 15 Aug 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
CEO and President, Director
Signature
/s/ Josh Riggs
Issuer symbol
OCX
Transactions as of
15 Aug 2023
Net transactions value
$0
Form type
4
Filing time
17 Aug 2023, 18:57:33 UTC
Previous filing
13 Jun 2023
Next filing
15 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +40,000 $0.000000 40,000 15 Aug 2023 Common Stock 40,000 $3.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025.